Central Nervous System News and Research

RSS

LFA seeks grant applications to address important areas of lupus research

The Lupus Foundation of America (LFA) seeks grant applications to advance the science and medicine of lupus and to help improve the quality of lives of all people affected by this disease. The LFA is seeking grant applications to address the following areas of lupus research: cutaneous (skin) lupus, pediatric lupus, adult stem cell transplantation, and neuropsychiatric lupus, which affects the brain and nervous system.

10 Feb 2012

Single fibronectin injection can prevent chronic pain development after SCI

Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes.

9 Feb 2012

LFA announces new grants for critical areas of lupus research

Today, the Lupus Foundation of America (LFA) announced new research grants awarded to fund critical areas of research where gaps exist in the understanding and knowledge of lupus including: pediatric lupus, cutaneous (skin) lupus, mid-to-late stage translational research, adult stem cells, and neuropsychiatric lupus, which affects the brain and nervous system.

9 Feb 2012

Exposure to manganese may increase risk of clumsiness in former welders

Welders who are exposed to manganese from welding fumes, risk developing increased clumsiness - and the result may remain decades after exposure has ceased. This is the finding of a study at the University of Gothenburg, Sweden, of former shipyard workers.

7 Feb 2012

Concussions linked with number of hits received by football players

A two-year study of high school football players suggests that concussions are likely caused by many hits over time and not from a single blow to the head, as commonly believed.

3 Feb 2012

The Methodist Hospital now offers advanced rehabilitation system for treatment of foot drop

The Methodist Hospital Outpatient Rehabilitation Center now offers an advanced rehabilitation system for the treatment of foot drop in people with mobility issues caused by stroke, traumatic brain injury, multiple sclerosis, cerebral palsy and spinal cord injury.

2 Feb 2012

Omeros, BioMed sign new 15-year lease agreement

BioMed Realty Trust, Inc. announced today the signing of a new 15-year lease with Omeros Corporation for BioMed's Waterfront Research Center property located in Seattle, Washington.

1 Feb 2012

Study finds no link between BDV and psychiatric illness

Over the past 30 years, numerous studies have linked Borna disease virus (BDV) with mental illnesses such as bipolar disorder, schizophrenia, anxiety disorder and dementia. Genetic fragments and antibodies to this RNA virus, which causes behavior disorders in a range of mammals and birds, have been found to be prevalent in psychiatric patients, but study results have been inconsistent. Now, the first blinded, case-control study to examine this issue finds no association between the virus and psychiatric illness.

1 Feb 2012

First evidence links cancer to mutations in genes involved in DNA organization

St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project provides first evidence linking cancer to mutations in genes involved in DNA organization

30 Jan 2012

TONIX receives net proceeds of $1.9M in private placement

TONIX Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, has received net proceeds of approximately $1.9 million in a private placement offering to institutional and accredited investors.

23 Jan 2012

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).

23 Jan 2012

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

19 Jan 2012

Hormone that burns energy discovered

Boston scientists have found a hormone that is secreted by muscles during exercise and boosts the amount of energy the body burns. This hormone – irisin – could be the first step in development of new drugs for obesity, diabetes, and other diseases feel researchers. A Boston startup company, Ember Therapeutics, has already licensed the technology and is working to develop a form of the hormone that could be used as a drug that would mimic some of the benefits of exercise.

16 Jan 2012

Amarantus receives U.S. patent titled, 'Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof'

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.

12 Jan 2012

Saladax increases claims in immunoassay space to 15 patents

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space.

11 Jan 2012

TCM therapy makes fertility treatments far more effective: Study

Traditional Chinese medicine has long been used to ease pain, treat disease, boost fertility, and prevent miscarriage. Known in the Western medical community by its acronym TCM, these traditional remedies include herbal preparations and acupuncture. Now Tel Aviv University researchers have discovered that a combination of TCM therapy and intrauterine insemination (IUI) is a winning solution for hopeful mommies who are having trouble conceiving.

10 Jan 2012

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

Georgia Bio announces 2012 Deals of the Year for pharma, biopharma and medical device companies

Georgia Bio announced its 2012 Deals of the Year for pharmaceutical, biopharmaceutical and medical device companies in four categories - public and private financings, fast growing companies, acquisitions and SBIR grants - reflecting a broad range of activity.

From Medtronic 7 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell.

7 Jan 2012